帕罗西汀联用小剂量多塞平治疗躯体化障碍的临床研究

目的:比较单用帕罗西汀和联用小剂量多塞平治疗躯体化障碍的疗效和不良反应。方法:将280例躯体化障碍患者随机分为单用组与联用组,治疗8周后以临床疗效大体评定量表(CGI)、症状自评量表(SCL-90)评价疗效,副反应量表(TESS)评价不良反应。结果:治疗8周后,CGI评分总有效率单用组为87.5%,联用组为93.8%(P<0.05);2组治疗前、后SCL-90躯体化障碍因子分比较差异有统计学意义(P<0.01),治疗后2组间比较差异也有统计学意义(P<0.05)。不良反应发生率2组间比较差异无统计学意义(P>0.05)。结论:帕罗西汀联用多塞平治疗躯体化障碍疗效优于单用帕罗西汀,且不增加不良反应。

Clinical Study on Paroxetine Combined with Small Dose of Doxepin for Somatization Disorder

OBJECTIVE： To evaluate the efficacy and adverse effects of paroxetine alone or in combination with small dose of doxepin for somatization disorder. METHODS： 280 patients with somatization disorder were randomly assigned to receive paroxetine alone or in combination with small dose of doxepin for 8 weeks. Clinical global impression scale （CGI） and symptom check list （SCL-90） were used to assess the efficacy, and treatment emergent symptom scale （TESS） was used to assess the adverse effects. RESULTS： After treatment for 8 weeks, CGI score showed the total effective rate was 87.5% in the patients treated with paroxetine alone versus 93.8% in those treated with paroxetine in combination with small dose of doxepin（P〈0.05） . There were statistical differences in the two groups in SCL - 90 score of somatization disorder after treatment as compared with before treatment（P〈 0.01）, and the differences between the two groups after treatment were also significant （P 0.05）, but the difference in adverse drug reactions was not significant（P 〉0.05）. CONCLUSION： Paroxetine in combination with small dose doxepin showed better efficacy for somatization disorder yet without increasing adverse effects as compared with paroxetine alone.